Tratamento com fator neurotrófico derivado da linhagem das células gliais em pacientes com doença de parkinson / Treatment with glial cell line-derived neurotrophic factor in patients with parkinson disease

Marco Taneda

Abstract


Introdução: A doença de Parkinson (DP) é o segundo distúrbio neurodegenerativo progressivo mais comum e afeta a qualidade de vida de milhões de pessoas em todo o mundo. Um possível tratamento é a utilização de fator neurotrófico derivado da linhagem das células gliais (GDNF), que promove a sobrevivência de neurônios dopaminérgicos. Entretanto, essa neurotrofina não é capaz de atravessar a barreira hematoencefálica, o que dificulta o seu uso clínico. Objetivo: Investigar a potencial utilização clínica do GDNF em pacientes com DP. Método: Trata-se de uma revisão sistemática da literatura que buscou artigos das bases de dados do Medline e Web of Science, publicados no período de 01 de janeiro de 1989 até 31 de dezembro de 2019. Resultados: Nesta pesquisa, foram identificados treze estudos de ensaios clínicos que apresentaram resultados dos mais diversos, os quais foram discutidos neste artigo. Conclusão: Existem muitas divergências nos resultados apresentados pelos autores, sendo necessário a realização de mais estudos clínicos.

 


Keywords


Doença de Parkinson. Fator neurotrófico derivado da linhagem das células gliais. Ensaio clínico. Neuroproteção. Fatores de crescimento. Família de proteínas GDNF.

References


ALEXANDER, G.E. Biology of Parkinson’s disease: Pathogenesis and pathophysiology of a multisystem neurodegenerative disorder. Dialogues Clin. Neurosci. 2004, 6(3): 259-280. Disponível em: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3181806/pdf/DialoguesClinNeurosci-6-259.pdf

ANTONY, P.M.A.; DIEDERICH, N.J.; KRUGER, R.; BALLING, R. The hallmarks of Parkinson´s disease. FEBS J. 2013; 280 (23): 5981-93. DOI: 10.1111/febs.12335.

BARTUS RT, BAUMANN TL, SIFFERT J, HERZOG CD, ALTERMAN R, BOULIS N, TURNER DA, STACY M, LANG AE, LOZANO AM, OLANOW CW. Safety/feasibility of targeting the substantia nigra with AAV2-neurturin in Parkinson’s patients. Neurology. 2013; 80(18):1698–1701. Disponível em: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3716474/pdf/WNL204989.pdf

BEITZ, J.M. Parkinson's Disease: A Review. Front Biosci. 2014, 1;6: 65-74. Doi: 10.2741/s415.

BLITS, B.; PETRY, H. Perspective on the Road toward Gene Therapy for Parkinson’s Disease. Front Neuroanat. 2017. Jan 9;10:128. doi: 10.3389/fnana.2016.00128

BOWENKAMP, K.E.; LAPCHAK, P.A.; HOFFER, B.J.; MILLER, P.J.; BICKFORD, P.C. Intracerebroventricular glial cell line-derived neurotrophic factor improves motor function and supports nigrostriatal dopamine neurons in bilaterally 6-hydroxydopamine lesioned rats. Exp. Neurol. 1997, 145, 104–117. doi: 10.1006/exnr.1997.6436.

ESLAMBOLI, A. Assessment of GDNF in Primate Models of Parkinson's Disease: Comparison With Human Studies. Rev Neurosci. 2005. 16(4):303-10. doi: 10.1515/revneuro.2005.16.4.303.

FEARNLEY JM, LEES AJ. Ageing and Parkinson’s disease: substantia nigra regional selectivity. Brain. 1991; 114 (Pt 5): 2283–2301. doi: 10.1093/brain/114.5.2283

GALVÃO, T.F; PANSANI, T.S.A; HARRAD, D. Principais itens para relatar Revisões

sistemáticas e Meta-análises: A recomendação PRISMA. Epidemiol. Serv. Saúde. 2015. 24(2). doi: 10.5123/S1679-49742015000200017.

GERHARDT, G.A.; CASS, W.A.; HUETTL, P.; BROCK, S.; ZHANG, Z.; GASH, D.M. GDNF improves dopamine function in the substantia nigra but not the putamen of unilateral MPTP-lesioned rhesus monkeys. Brain Res. 1999, 817, 163–171. https://doi.org/10.1016/S0006-8993(98)01244-X

GILL, S.S.; PATEL, N.K.; HOTTON, G.R.; O’SULLIVAN, K.; MCCARTER, R.; BUNNAGE, M.; BROOKS, D.J.; SVENDSEN, C.N.; HEYWOOD,P. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat. Med. 2003, 9, 589–595. doi: 10.1038/nm850.

HUTTUNEN, H.J.; SAARMA, M. CDNF Protein Therapy in Parkinson’s Disease. Cell Transplant. 2019. Apr; 28 (4): 349-366. doi: 10.1177/0963689719840290.

KELLS AP, EBERLING J, SU X, PIVIROTTO P, BRINGAS J, HADACZEK P, NARROW WC, BOWERS WJ, FEDEROFF HJ, FORSAYETH J, BANKIEWICZ KS. Regeneration of the MPTP-lesioned dopaminergic system after convection-enhanced delivery of AAV2-GDNF. J Neurosci. 2010. 30, 9567-9577. Disponível em: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2914692/pdf/zns9567.pdf

KIM, S.D.; ALLEN, N.E.; CANNING, C.G.; FUNG, V.S.C. Parkinson Disease. Handb Clin Neurol. 2018; 159: 173-193. doi: 10.1016/B978-0-444-63916-5.00011-2

KIRIK, D.; GEORGIEVSKA, B.; ROSENBLAD, C.; BJÖRKLUND, A. Delayed infusion of GDNF promotes recovery of motor function in the partial lesion model of Parkinson’s disease. Eur. J. Neurosci. 2001, 13, 1589–1599. https://doi.org/10.1046/j.0953-816x.2001.01534.x

KORDOWER, J.H.; PALFI, S.; CHEN, E.-Y.; MA, S.Y.; SENDERA, T.; COCHRAN, E.J.; MUFSON, E.J.; PENN, R.; GOETZ, C.G.; COMELLA, C.D. Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson’s disease. Ann. Neurol. 1999, 46, 419–424. https://doi.org/10.1002/1531-8249(199909)46:3<419::AID-ANA21>3.0.CO;2-Q

KORDOWER JH, OLANOW CW, DODIYA HB, CHU Y, BEACH TG, ADLER CH, HALLIDAY GM, BARTUS RT. Disease duration and the integrity of the nigrostriatal system in Parkinson’s disease. Brain. 2013; 136 (Pt 8): 2419–2431. doi: 10.1093/brain/awt192

LANG, A.E.; GILL, S.; PATEL, N.K.; LOZANO, A.; NUTT, J.G.; PENN, R.; BROOKS, D.J.; HOTTON, G.; MORO, E.; HEYWOOD, P.; et al. Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann. Neurol. 2006, 59, 459–466. https://doi.org/10.1002/ana.20737

LAPCHAK, P.A.; MILLER, P.J.; JIAO, S. Glial cell line-derived neurotrophic factor induces the dopaminergic and cholinergic phenotype and increases locomotor activity in aged Fischer 344 rats. Neuroscience 1997, 77, 745–752. doi: 10.1016/s0306-4522(96)00492-7.

LIMOUSIN, P.; POLLAK, P.; BENAZZOUZ, A.; HOFFMANN, D.; LE BAS, J.-F.; PERRET, J.E.; BENABID, A.-L.; BROUSSOLLE, E. Effect on parkinsonian signs and symptoms of bilateral subthalamic nucleus stimulation. Lancet 1995, 345, 91–95. https://doi.org/10.1016/S0140-6736(95)90062-4

MARKS, W.J., JR.; OSTREM, J.L.; VERHAGEN, L.; STARR, P.A.; LARSON, P.S.; BAKAY, R.A.; TAYLOR, R.; CAHN-WEINER, D.A.; STOESSL, A.J.; OLANOW, C.W.; et al. Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson’s disease: An open-label, phase I trial. Lancet Neurol. 2008, 7, 400–408. DOI: https://doi.org/10.1016/S1474-4422(08)70065-6

MARKS, W.J.; BARTUS, R.T.; SIFFERT, J.; DAVIS, C.S.; LOZANO, A.; BOULIS, N.; VITEK, J.; STACY, M.; TURNER, D.; VERHAGEN, L.; et al. Gene delivery of AAV2-neurturin for Parkinson’s disease: A double-blind, randomised, controlled trial. Lancet Neurol. 2010, 9, 1164–1172. doi: 10.1016/S1474-4422(10)70254-4.

MARKS, W.J.; BAUMANN, T.L.; BARTUS, R.T. Long-Term Safety of Patients With Parkinson's Disease Receiving rAAV2-Neurturin (CERE-120) Gene Transfer. Hum Gene Ther. 2016 Jul;27(7):522-7. doi: 10.1089/hum.2015.134.

NUTT, J.G.; BURCHIEL, K.J.; COMELLA, C.L.; JANKOVIC, J.; LANG, A.E.; LAWS, E.R., JR.; LOZANO, A.M.; PENN, R.D.; SIMPSON, R.K., JR.; STACY, M.; et al. Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology 2003, 60, 69–73. DOI: https://doi.org/10.1212/WNL.60.1.69.

OIWA, Y.; NAKAI, K.; ITAKURA, T. Histological effects of intraputaminal infusion of glial cell line-derived neurotrophic factor in Parkinson disease model macaque monkeys. Neurol. Med. Chir. 2006, 46, 267–275. https://doi.org/10.2176/nmc.46.267

OLANOW, C.W.; BARTUS, R.T.; BAUMANN, T.L.; FACTOR, S.; BOULIS, N.; STACY, M.; TURNER, D.A.; MARKS, W.; LARSON, P.; STARR, P.A.; et al. Gene Delivery of Neurturin to Putamen and Substantia Nigra in Parkinson Disease: A Double-Blind, Randomized, Controlled Trial. Ann Neurol. 2015 Aug;78(2):248-57. doi: 10.1002/ana.24436.

PATEL, N.K.; GILL, S.S. GDNF Delivery for Parkinson's Disease. Acta Neurochir Suppl. 2007. 97(Pt 2):135-54. doi: 10.1007/978-3-211-33081-4_16

QUINTINO, L.; AVALLONE, M.; BRANNSTROM, E.; KAVANAGH, P.; LOCKOWANDT, M.; JARENO, P.G.; BREGER, L.S.; LUNDBERG, C. GDNF-mediated Rescue of the Nigrostriatal System Depends on the Degree of Degeneration. Gene Ther. 2019. Feb;26(1-2):57-64. doi: 10.1038/s41434-018-0049-0.

SALVATORE MF, AI Y, FISCHER B, ZHANG AM, GRONDIN RC, ZHANG Z, et al. Point source concentration of GDNF may explain failure of phase II clinical trial. Exp Neurol 2006; 202: 497–505. https://doi.org/10.1016/j.expneurol.2006.07.015

SLEVIN, J.T.; GERHARDT, G.A.; SMITH, C.D.; GASH, D.M.; KRYSCIO, R.; YOUNG, B. Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor. J. Neurosurg. 2005, 102, 216–222. doi: 10.3171/jns.2005.102.2.0216.

SLEVIN, J.T.; GASH, D.M.; SMITH, C.D.; GERHARDT, G.A.; KRYSCIO, R.; CHEBROLU, H.; WALTON, A.; WAGNER, R.; YOUNG, A.B. Unilateral intraputaminal glial cell line–derived neurotrophic factor in patients with Parkinson disease: response to 1 year each of treatment and withdrawal. Neurosurg Focus. 2006. May 15; 20(5): E1. doi: 10.3171/foc.2006.20.5.2.

SMITH, M.P.; CASS, W.A. GDNF reduces oxidative stress in a 6-hydroxydopamine model of Parkinson’s disease. Neurosci. Lett. 2007, 412, 259–263. Disponível em: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1847408/pdf/nihms-17420.pdf

SMITH. R.C.; BRYAN, L.M.; MITCHELL, P.J.; LEUNG, D.; GHANEM, M.; WILSON, J.M.; HANSON, J.C.; SOSSICK, S.; COOPER, J.; HUANG, L.; MERCHANT, K.M.; LU, J.; NEIL, M.J.O. Increased Brain Bio-Distribution and Chemical Stability and Decreased Immunogenicity of an Engineered Variant of GDNF. Exp Neurol. 2015 May; 267: 165-76. doi: 10.1016/j.expneurol.2015.03.002.

STAUDT, M.D.; SEBASTIANO, A.R.D.; XU, H.; JOG, M.; SCHMID, S.; FOSTER, P.; HEBB, M.O. Advances in Neurotrophic Factor and Cell-Based Therapies for Parkinson's Disease: A Mini-Review. Gerontology. 2016; 62(3): 371-80. doi: 10.1159/000438701.

TOMAC, A.; LINDQVIST, E.; LIN, L.F.; OGREN, S.O.; YOUNG, D.; HOFFER, B.J.; OLSON, L. Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo. Nature 1995, 373, 335–339. doi: 10.1038/373335a0.

TORRES, N., MOLET, J., MORO, C., MITROFANIS, J., BENABID, A.L. Neuroprotective Surgical Strategies in Parkinson’s Disease: Role of Preclinical Data. Int. J. Mol. Sci. 2017, 18, 2190. Doi:10.3390/ijms18102190.

TYSNES, O.B.; STORSTEIN, A. Epidemiology of Parkinson´s disease. J Neural Transm. 2017; 124(8): 901-905. DOI: 10.1007/s00702-017-1686-y

WHONE, A.; LUZ, M.; BOCA, M.; WOOLLEY, M.; MOONEY, L.; DHARIA, S.; BROADFOOT, J.; CRONIN, D.; SCHROERS, C.; BARUA, N.U.; LONGPRE, L. et al. Randomized Trial of Intermittent Intraputamenal Glial Cell Line-Derived Neurotrophic Factor in Parkinson's Disease. Brain. 2019a. Mar 1; 142(3): 512-525. doi: 10.1093/brain/awz023.

WHONE, A.L.; BOCA, M.; LUZ, M.; WOOLLEY, M.; MOONEY, L.; DHARIA, S.; BROADFOOT, J.; CRONIN, D.; SCHROERS, C.; BARUA, N.U.; LONGPRE, L.; BARCLAY, C.L.; BOIKO, C.; et al. Extended Treatment With Glial Cell Line-Derived Neurotrophic Factor in Parkinson's Disease. J Parkinsons Dis. 2019b; 9(2): 301-313. doi: 10.3233/JPD-191576.




DOI: https://doi.org/10.34117/bjdv6n6-197

Refbacks

  • There are currently no refbacks.